Skip to content Skip to sidebar Skip to footer


Apellis attempts to clear the air around Syfovre safety as eye drug launch gains steam

For Apellis Pharmaceuticals, the emergence of rare but serious side effects has cast a pall over the launch of the company’s geographic atrophy med Syfovre. | While touting the “strong commercial execution” of Syfovre’s launch, Apellis’ CEO Cedric Francois, M.D., Ph.D., admitted the company has become aware of several cases of retinal vasculitis tied to…

Read More

After quitting FDA adcomm in protest of Aduhelm decision, Harvard's Aaron Kesselheim finds agency has an approval bias

The ill-fated launch of Biogen’s Alzheimer’s disease treatment Aduhelm raised many questions, including this: Why did the FDA sign off on the drug after an independent advisory committee recommende | A study of FDA advisory committee meetings between 2010 and 2021 shows that the regulator leaned heavily toward approval. When a panel recommended approval, the…

Read More

Biogen, amid layoffs, ponies up $7.3B for rare disease specialist Reata and potential blockbuster Skyclarys

On Monday during a quarterly earnings call, when Biogen CEO Chris Viehbacher was asked about the company’s potential to execute M&A, he randomly offered “we’ve got, I think, about $7.3 billion | Biogen has revealed a proposal to acquire Reata Pharmaceuticals for $7.3 billion. The Texas-based rare disease specialist brings newly approved Skyclarys, the…

Read More

Biogen Digital Health | Biogen

We aspire to transform patients’ lives by making personalized and digital medicine a reality. Powered by data science and digital technologies, we aspire to drive solutions to advance research, clinical care and patient empowerment. We believe that now, more than ever, biology and technology should come together to better meet patient needs while enabling a…

Read More